(Q37310828)

19 August 2017

1 reference

title

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future (English)

1 reference

19 August 2017

main subject

cardiovascular disease

1 reference

John W Eikelboom

2

0 references

author name string

Nina C Raju

series ordinal

1

1 reference

19 August 2017

Jack Hirsh

series ordinal

3

1 reference

19 August 2017

publication date

28 October 2008

1 reference

Nature Clinical Practice Cardiovascular Medicine

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

766-780

1 reference

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

A dual thrombin receptor system for platelet activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Domains specifying thrombin–receptor interaction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

The roles of proteinase-activated receptors in the vascular physiology and pathophysiology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Structure and stereochemistry of the active metabolite of clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Bleeding and management of bleeding

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in coll

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

[Stent thrombosis in the modern era: incidence, outcome and predictive factors]

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

1 reference

7 January 2021

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Pharmacokinetics of clopidogrel after administration of a high loading dose

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

The disposition of prasugrel, a novel thienopyridine, in humans.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

1 reference

7 January 2021

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1372

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO1372

1 reference

19 August 2017

1 reference